Table 3.
Statistical tests evaluating the predictive value of MRI in detecting nodal status after neoadjuvant therapy overall and by clinical node status.
| Overall Cohort | |||
|---|---|---|---|
| Neoadjuvant chemotherapy (n = 46) | Neoadjuvant endocrine therapy (n = 33) | P-Value | |
| Sensitivity | 37.9% | 66.7% | 0.0116 |
| Specificity | 70.6% | 66.7% | 0.7117 |
| Negative predictive value | 40.0% | 70.6% | 0.0072 |
| Positive predictive value | 68.8% | 62.5% | 0.5594 |
| Overall accuracy | 50.0% | 66.7% | 0.1393 |
| Neoadjuvant chemotherapy Cohort | |||
| Clinically node negative (n = 24) | Clinically node positive (n = 22) | P-Value | |
| Sensitivity | 20.0% | 47.4% | 0.0485 |
| Specificity | 78.6% | 33.3% | 0.0019 |
| Negative predictive value | 57.9% | 9.1% | 0.0005 |
| Positive predictive value | 40.0% | 81.2% | 0.0044 |
| Overall accuracy | 54.2% | 45.5% | 0.5555 |
| Neoadjuvant endocrine therapy cohort | |||
| Clinically node negative (n = 25) | Clinically node positive (n = 8) | P-Value | |
| Sensitivity | 42.9% | 87.5% | 0.0277 |
| Specificity | 66.7% | N/A1 | |
| Negative predictive value | 75.0% | 0.0% | 0.0002 |
| Positive predictive value | 33.3% | 100.0% | 0.001 |
| Overall accuracy | 60.0% | N/Aa | |
aThere were no clinically node positive patients who received endocrine therapy and were pathologically node negative; as such, specificity and accuracy of post-treatment MRI cannot be calculated for this subset.